- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04170348
Daily Vitamin D for Sickle-cell Respiratory Complications (ViDAS-2)
This study aims to answer the question whether daily oral vitamin D supplementation can reduce the risk of respiratory or lung complications in children and adolescents with sickle cell disease. Respiratory problems are the leading causes of sickness and of death in sickle cell disease. The investigators hypothesize that daily oral vitamin D3, compared to monthly oral vitamin D, will rapidly increase circulating vitamin D3, and reduce the rate of respiratory complications by 50% or more within the first year of supplementation in children and adolescents with sickle cell disease.
This study is funded by the FDA Office of Orphan Products Development (OOPD).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a 2-year controlled, double-blind, randomized Phase 2 clinical trial comparing the efficacy in reducing the rate of respiratory events in sickle-cell disease of daily oral vitamin D3 (3,333 IU/d) with monthly bolus oral vitamin D3, (100,000 IU/mo) as a control. The scientific premise of the clinical trial is that circulating concentrations of vitamin D3, the parent compound, are the principal determinant of the anti-infective and immunomodulatory effects of supplementation.
Eligible participants will be initially screened to determine their blood vitamin D levels. Those with 25-hydroxyvitamin D levels between 5 and 60 ng/mL will be assigned by chance to one of the two arms for 24 months. Participants will be checked every month and will have periodic blood and urine tests to monitor for any side effects of the study treatments. Children above 5 y/o who can cooperate and understand the procedure will have lung function test at baseline and at 24 months. Showing that a monthly dose of vitamin D reduces lung infections, asthma and the acute chest syndrome could help establish this simple, low-cost treatment as a way to decrease sickness and deaths in children and adolescents with sickle-cell disease.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of sickle cell disease (Hb SS, Hb SC, Hb S-Beta-thalassemia)
- Age 3-20 years old
Exclusion Criteria:
- Patient unwilling or unable to provide written informed consent (and assent, if applicable)
- Patient unable or unwilling to comply with requirements of the clinical trial
- Participation in another clinical trial
- Current diagnosis of rickets
- History of hypercalcemia or diagnosis of any medical condition associated with hypercalcemia, including primary hyperparathyroidism, malignancy, sarcoidosis, tuberculosis, granulomatous disease, familial hypocalciuric hypercalcemia
- Current use of corticosteroids, excluding inhaled steroids
- Current use of anticonvulsants (phenytoin, phenobarbital, carbamazepine)
- Therapy with thiazide diuretics or lithium carbonate
- Known liver or renal disease
- Patients taking medications for pulmonary complications of sickle cell disease not on a stable dose of medications, as defined by a change in medications or doses within the three months prior to study entry
- Patients on chronic red blood cell transfusion therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Daily oral vitamin D3
Oral vitamin D3, 3,333 IU
|
Oral vitamin D3, 3,333 IU, will be administered daily.
Other Names:
|
Active Comparator: Monthly bolus oral vitamin D3
Bolus oral vitamin D3, 100,000 IU
|
Bolus oral vitamin D3, 100,000 IU, will be administered monthly.
Other Names:
Participants randomized to receive once monthly oral bolus of vitamin D3, will receive placebo on all other days of the month.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Respiratory Events
Time Frame: Screening up to month 24
|
Annual rate of respiratory events will be calculated as the sum of respiratory infection, asthma exacerbation, and acute chest syndrome, as ascertained by use of a validated questionnaire.
|
Screening up to month 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Forced Vital Capacity (FVC)
Time Frame: Baseline and month 24
|
Change forced vital capacity (FVC; % predicted) from baseline
|
Baseline and month 24
|
Change in Forced Expiratory Volume in 1 second (FEV1)
Time Frame: Baseline and month 24
|
Change in Forced Expiratory Volume in 1 second (FEV1; % predicted) from baseline.
|
Baseline and month 24
|
Change in Forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity ratio
Time Frame: Baseline and month 24
|
Change in Forced Expiratory Volume in 1 second (FEV1; % predicted)/Forced Vital Capacity (FVC) [FEV1/FVC] % predicted from baseline.
|
Baseline and month 24
|
Change in Forced Expiratory Flow at 25%-75% vital capacity (FEF25-75)
Time Frame: Baseline and month 24
|
Change in Forced Expiratory Flow at 25%-75% vital capacity (FEF25-75) % predicted from baseline.
|
Baseline and month 24
|
Change in ratio of Residual Lung Volume (RV) to Total Lung Capacity (TLC)
Time Frame: Baseline and month 24
|
Change in per cent of the ratio of Residual Lung Volume (RV) to Total Lung Capacity (RV/TLC) from baseline.
|
Baseline and month 24
|
Change in Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO)
Time Frame: Baseline and month 24
|
Change in Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO; % predicted) from baseline
|
Baseline and month 24
|
Change in Fractional Concentration of Exhaled Nitric Oxide (FENO)
Time Frame: Baseline and month 24
|
Change in Fractional Concentration of Exhaled Nitric Oxide (FENO) in parts per billion (ppb) from baseline
|
Baseline and month 24
|
Change in Maximum Inspiratory Pressure (MIP)
Time Frame: Baseline and month 24
|
Change in Maximum Inspiratory Pressure (MIP; cm H2O) from baseline
|
Baseline and month 24
|
Change in Maximum Expiratory Pressure (MEP)
Time Frame: Baseline and month 24
|
Change in Maximum Expiratory Pressure (MEP; cm H2O) from baseline
|
Baseline and month 24
|
Change in interleukin 2 (IL 2) concentration
Time Frame: Baseline up to month 24
|
Change in serum interleukin 2 concentration (IL 2; pg/mL ) from baseline
|
Baseline up to month 24
|
Change in interleukin 4 (IL 4) concentration
Time Frame: Baseline up to month 24
|
Change in serum interleukin 4 concentration (IL 4; pg/mL ) from baseline
|
Baseline up to month 24
|
Change in interleukin 5 (IL 5) concentration
Time Frame: Baseline up to month 24
|
Change in serum interleukin 5 concentration (IL 5; pg/mL ) from baseline
|
Baseline up to month 24
|
Change in interleukin 13 (IL 13) concentration
Time Frame: Baseline up to month 24
|
Change in serum interleukin 13 concentration (IL 13; pg/mL ) from baseline
|
Baseline up to month 24
|
Change in interferon gamma (IFN gamma). concentration
Time Frame: Baseline up to month 24
|
Change in serum interferon gamma concentration (IFN gamma; pg/mL ) from baseline
|
Baseline up to month 24
|
Change in interleukin 10 (IL 10) concentration
Time Frame: Baseline up to month 24
|
Change in serum interleukin 10 concentration (Iinterleukin 10; pg/mL ) from baseline
|
Baseline up to month 24
|
Change in Transforming Growth Factor beta (TGF beta)
Time Frame: Baseline up to month 24
|
Change in serum Transforming Growth Factor beta (TGF beta; pg/mL ) from baseline
|
Baseline up to month 24
|
Change in blood hemoglobin concentration (Hb)
Time Frame: Baseline up to month 24
|
Change in blood hemoglobin concentration (Hb; g/dL) from baseline
|
Baseline up to month 24
|
Change in blood platelet concentration
Time Frame: Baseline up to month 24
|
Change in blood platelet concentration (platelets/mL) from baseline
|
Baseline up to month 24
|
Change in serum C-reactive protein (CRP)
Time Frame: Baseline up to month 24
|
Change in serum C-reactive protein (CRP; mg/L) from baseline
|
Baseline up to month 24
|
Change in interleukin 1alpha (IL 1alpha) concentration
Time Frame: Baseline up to month 24
|
Change in serum interleukin 1alpha (IL 1alpha; pg/mL) from baseline
|
Baseline up to month 24
|
Change in interleukin 1beta (IL 1beta) concentration
Time Frame: Baseline up to month 24
|
Change in serum interleukin 1beta (IL 1beta; pg/mL) from baseline
|
Baseline up to month 24
|
Change in Tumor Necrosis Factor alpha (TNF alpha) concentration
Time Frame: Baseline up to month 24
|
Change in serum Tumor Necrosis Factor alpha (TNF alpha; pg/mL) from baseline
|
Baseline up to month 24
|
Change in C-terminal telopeptides of Type I collagen (CTX)
Time Frame: Baseline up to month 24
|
Change in serum C-terminal telopeptides of Type I collagen (CTX; ng/mL) from baseline
|
Baseline up to month 24
|
Change in intact N-terminal propeptide of type I procollagen (P1NP)
Time Frame: Baseline up to month 24
|
Chang in serum intact N-terminal propeptide of type I procollagen (P1NP; µg/L) from baseline.=
|
Baseline up to month 24
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gary M Brittenham, MD, Columbia University
- Principal Investigator: Margaret T Lee, MD, Columbia University
Publications and helpful links
General Publications
- Lee MT, Kattan M, Fennoy I, Arpadi SM, Miller RL, Cremers S, McMahon DJ, Nieves JW, Brittenham GM. Randomized phase 2 trial of monthly vitamin D to prevent respiratory complications in children with sickle cell disease. Blood Adv. 2018 May 8;2(9):969-978. doi: 10.1182/bloodadvances.2017013979.
- Williams KM, Lee MT, Licursi M, Brittenham GM, Fennoy I. Response to Long-term Vitamin D Therapy for Bone Disease in Children With Sickle Cell Disease. J Pediatr Hematol Oncol. 2018 Aug;40(6):458-461. doi: 10.1097/MPH.0000000000001155.
- De A, Anekwe CV, Kattan M, Yao Y, Jin Z, Brittenham GM, Lee MT. Validation of a Questionnaire to Identify Respiratory Tract Infections in Children With Sickle Cell Disease. J Pediatr Hematol Oncol. 2021 Jul 1;43(5):e661-e665. doi: 10.1097/MPH.0000000000002164.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Hematologic Diseases
- Genetic Diseases, Inborn
- Avitaminosis
- Malnutrition
- Hemoglobinopathies
- Lung Diseases
- Vitamin D Deficiency
- Anemia
- Anemia, Sickle Cell
- Respiratory Tract Infections
- Vitamin A Deficiency
- Nutrition Disorders
- Respiration Disorders
- Respiratory Tract Diseases
- Deficiency Diseases
- Acute Chest Syndrome
- Anemia, Hemolytic
- Anemia, Hemolytic, Congenital
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Micronutrients
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Chelating Agents
- Sequestering Agents
- Vitamin D
- Cholecalciferol
- Vitamins
- Ergocalciferols
- Trientine
Other Study ID Numbers
- AAAS0396
- R01FD006372 (U.S. FDA Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiratory Tract Infections
-
Vakzine Projekt Management GmbHFGK Clinical Research GmbHUnknownInfection, Respiratory TractGermany
-
GlaxoSmithKlineCompletedInfections, Respiratory TractUnited States
-
GlaxoSmithKlineCompletedInfections, Respiratory TractGermany
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedInfections, Respiratory TractUnited States
-
GlaxoSmithKlineCompletedInfections, Respiratory TractAustralia
-
GlaxoSmithKlineCompletedInfections, Respiratory Tract
-
GlaxoSmithKlineCompletedInfections, Respiratory TractUnited States
-
GlaxoSmithKlineCompletedInfections, Respiratory Syncytial VirusUnited States
-
GlaxoSmithKlineCompletedInfections, Respiratory Syncytial VirusCanada
Clinical Trials on Daily oral vitamin D3, 3,333 IU
-
King Faisal Specialist Hospital & Research CenterWithdrawnVitamin D DeficiencySaudi Arabia
-
Augusta UniversityCompletedObesity | Overweight | Vitamin D DeficiencyUnited States
-
Rutgers UniversityCompleted
-
University of California, San FranciscoCompleted
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...RecruitingDengue FeverBangladesh
-
Brigham and Women's HospitalNational Center for Maternal and Child Health Research, Mongolia; Zuun Kharaa...CompletedVitamin D Deficiency | PregnancyMongolia
-
Medical University of South CarolinaEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompleted
-
Hasanuddin UniversityNot yet recruitingTuberculosis | SpondylitisIndonesia
-
Nationwide Children's HospitalOhio State UniversityUnknownVitamin D Deficiency | AsthmaUnited States
-
Boston UniversityCompletedVitamin D DeficiencyUnited States